|
|
|
| IL-2 Platform Profits With Bonum's John Mulligan And Neela Patel | Business of Biotech welcomes Neela Patel, a molecular biologist-turned-CBO, and John Mulligan, an academic-turned-founder of Bonum Therapeutics. They pull back the curtain on Bonum's transition from Good Therapeutics, which was fueled by a high-profile asset sale to Roche. The asset, a PD-1-regulated IL-2 program, was a product of a platform the new Bonum retains. Get the inside scoop on how these two retained IP and people through a fast, unique, and disruptive acquisition. |
|
|
|
|
Major events in the pharmaceutical industry will arise in 2024. Pharma companies and their market access teams should begin scenario planning to navigate the coming twists and turns. |
|
|
|
Discover additional biopharma industry executive responses to our 2024 finance and funding outlook questions. The responses expand the number and quality of perspectives from those featured in the Life Science Leader December print issue. |
|
|
|
Big Pharma will need to create new efficiencies and cost savings to overcome a growth gap years in the making. New uses of AI could help them get there. But is the sector ready to embrace new technology, and what are the best use cases? |
|
|
|
|
| Phases 1-3: Clinical Trials Overview | Various macroeconomic pressures faced by the biopharma industry led to a crunch in funding. In addition, economic and political factors contributed to a decline in clinical trials. |
|
|
|
|
Inside you will find more on: - Next-Gen RNA Therapies
- Outsourcing Outlook
- Leadership Lesson
- Clinical Trial Site Challenges
View the digital edition. |
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
| Connect With Life Science Leader: |
|
|
|
